- Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle (P
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings CallArcutis Biotherapeutics' next earnings callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Nov 4, 2026 at 4:30 PM ESTRegister
Arcutis Biotherapeutics, Inc. on 6ix
Story so far
- New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
- Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
- Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Earlier from Arcutis Biotherapeutics
- Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
- New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
- Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
- New campaign from Arcutis aims to expose the impact of psoriasis on physical, mental, and emotional wellbeing
- Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Later from Arcutis Biotherapeutics
- Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis
- Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis to Report Third Quarter Financial Results
- Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
Follow Arcutis Biotherapeutics into a list and get an email when it puts out news.
Follow Arcutis Biotherapeutics